<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01910038</url>
  </required_header>
  <id_info>
    <org_study_id>Bonnotte PHRC N 2012</org_study_id>
    <nct_id>NCT01910038</nct_id>
  </id_info>
  <brief_title>Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.</brief_title>
  <acronym>HORTOCI</acronym>
  <official_title>Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <brief_summary>
    <textblock>
      It has been reported that around 40% of GCA patients are able to decrease the prednisone dose&#xD;
      until 0.1 mg/Kg/d or less after 6 months of treatment. In this study, we hypothesized that&#xD;
      adding 3 months of tocilizumab to prednisone could increase the percentage from 40 to 70%.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 8, 2013</start_date>
  <completion_date type="Actual">June 13, 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients in remission with a dose of prednisone ≤ 0.1 mg/kg/day</measure>
    <time_frame>Week 26</time_frame>
    <description>Remission: absence of symptoms attributable to Giant Cell Arteritis and normalization of inflammatory markers (CRP&lt;10 mg/L and ESR&lt;30 mm/h).&#xD;
Relapse: recurrence of symptoms attributable to active GCA and/or increased levels of inflammatory markers (CRP≥10 mg/L and/or ESR≥30 mm/h). Elevation of inflammatory markers in the absence of GCA symptoms was considered relapse if it persisted at two time points at 1 week apart without any other obvious etiology than GCA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and type of adverse effects encountered</measure>
    <time_frame>Until Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of relapses</measure>
    <time_frame>Week 26 and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the first relapse</measure>
    <time_frame>Until Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors associated with the occurrence of relapse</measure>
    <time_frame>Until Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative dose of prednisone.</measure>
    <time_frame>Weeks 26 and 52</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Giant Cell Arteritis</condition>
  <arm_group>
    <arm_group_label>Prednisone+Tocilizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prednisone (0.7 mg/Kg/d and then progressively tapered to reach 0.1 mg/Kg/d at W24) + tocilizumab 8mg/Kg/4 weeks for a total of 4 infusions (S0, S4, S8, S12).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>corticoids+ tocilizumab 8mg/Kg/4 weeks</intervention_name>
    <arm_group_label>Prednisone+Tocilizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 50 years&#xD;
&#xD;
          -  GCA fulfilling ≥3/5 ACR criteria&#xD;
&#xD;
          -  Newly diagnosed GCA or relapsing GCA if treatments&#xD;
             (Glucocorticoids±immunosuppressants) have been stopped for at least 6 months&#xD;
&#xD;
          -  Glucocorticoids started for less than 21 days&#xD;
&#xD;
          -  Proof of large vessel vasculitis:&#xD;
&#xD;
               -  Positive temporal artery biopsy (TAB)&#xD;
&#xD;
               -  Aortitis, as defined by regular circumferential wall thickening ≥3mm in the&#xD;
                  absence of calcification and/or significant atheroma on angio-CT images; or a&#xD;
                  homogeneous vascular signal more intense than the liver on 18FDG-PET images.&#xD;
&#xD;
          -  For men and women of a child-bearing age, an effective method of contraception must be&#xD;
             used by the patient or his or her partner throughout the treatment with tocilizumab&#xD;
             (or placebo) and for 3 months after the end of the treatment. Breast-feeding is not&#xD;
             authorised until 3 months after the end of treatment with tocilizumab. Women not&#xD;
             considered at risk of pregnancy are those defined by menopause of at least one year or&#xD;
             surgically steriles (ligature of the fallopian tubes, bilateral ovariectomy or&#xD;
             hysterectomy)&#xD;
&#xD;
          -  Persons who have provided written informed consent&#xD;
&#xD;
          -  Persons covered by the National Health Insurance Agency&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  hospitalization in the previous year for drug or alcohol intoxication&#xD;
&#xD;
          -  current treatment for another autoimmune or inflammatory disease&#xD;
&#xD;
          -  known hypersensitivity to TCZ or one of its excipients or another human or murine&#xD;
             monoclonal antibody&#xD;
&#xD;
          -  treatment with anti-TNF-α, methotrexate, cyclophosphamide, dapsone, methylprednisolone&#xD;
             pulses or any other immunosuppressive or immunomodulatory drug or biotherapy within 6&#xD;
             months before inclusion&#xD;
&#xD;
          -  long-course systemic GC therapy&#xD;
&#xD;
          -  prednisone therapy &gt;1 mg/kg/day, whatever the duration&#xD;
&#xD;
          -  serious or chronic proven infections requiring hospitalization or intravenous&#xD;
             antibiotics within 30 days before inclusion&#xD;
&#xD;
          -  other proven infections that required antibiotics within 14 days before inclusion&#xD;
&#xD;
          -  opportunistic infections&#xD;
&#xD;
          -  evidence of active tuberculosis or latent tuberculosis (as deﬁned by a positive&#xD;
             interferon gamma release assay)&#xD;
&#xD;
          -  active chronic hepatitis B or C or HIV&#xD;
&#xD;
          -  cancer or lymphoproliferative disorders within the 5 years before inclusion (with the&#xD;
             exception of in situ cervical cancer and squamous or basal cell carcinoma with R0&#xD;
             resection)&#xD;
&#xD;
          -  past history of sigmoid diverticulitis&#xD;
&#xD;
          -  any active hepatic disease&#xD;
&#xD;
          -  hepatic failure; thrombocytopenia &lt;50 G/L&#xD;
&#xD;
          -  neutropenia &lt;0.5 G/L&#xD;
&#xD;
          -  history of moderate to severe congestive heart failure or demyelinating disease&#xD;
&#xD;
          -  recent stroke&#xD;
&#xD;
          -  current signs or symptoms of severe, progressive, or uncontrolled disease, not due to&#xD;
             GCA, which contraindicates TCZ&#xD;
&#xD;
          -  severe and uncontrolled hypercholesterolemia&#xD;
&#xD;
          -  high cardiovascular risk (former cerebral or coronary vascular event, or vascular risk&#xD;
             &gt;20% at 10 years according to the Framingham risk score [24]); dementia; non-compliant&#xD;
             patients&#xD;
&#xD;
          -  patients under ward of court, tutelage or legal guardianship.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Caen - Hôpital Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard HERRIOT</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux privés de Metz - Site Sainte Blandine</name>
      <address>
        <city>Metz</city>
        <zip>57045</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital COCHIN</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>July 17, 2013</study_first_submitted>
  <study_first_submitted_qc>July 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2013</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Arteritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

